BR122020007658B1 - Método para a remoção de agregados de elevado peso molecular utilizando cromatografia de hidroxiapatita - Google Patents
Método para a remoção de agregados de elevado peso molecular utilizando cromatografia de hidroxiapatita Download PDFInfo
- Publication number
- BR122020007658B1 BR122020007658B1 BR122020007658-5A BR122020007658A BR122020007658B1 BR 122020007658 B1 BR122020007658 B1 BR 122020007658B1 BR 122020007658 A BR122020007658 A BR 122020007658A BR 122020007658 B1 BR122020007658 B1 BR 122020007658B1
- Authority
- BR
- Brazil
- Prior art keywords
- antibody
- nacl
- column
- buffer
- sodium phosphate
- Prior art date
Links
- 238000004587 chromatography analysis Methods 0.000 title claims abstract description 48
- 238000000034 method Methods 0.000 title claims description 52
- 229910052588 hydroxylapatite Inorganic materials 0.000 claims abstract description 81
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 claims abstract description 81
- 238000002360 preparation method Methods 0.000 claims abstract description 80
- 239000000919 ceramic Substances 0.000 claims abstract description 23
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 182
- 239000011780 sodium chloride Substances 0.000 claims description 91
- 102000004169 proteins and genes Human genes 0.000 claims description 72
- 108090000623 proteins and genes Proteins 0.000 claims description 72
- 239000011347 resin Substances 0.000 claims description 71
- 229920005989 resin Polymers 0.000 claims description 71
- 239000001488 sodium phosphate Substances 0.000 claims description 71
- 229910000162 sodium phosphate Inorganic materials 0.000 claims description 71
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 claims description 71
- 239000000872 buffer Substances 0.000 claims description 33
- 239000011534 wash buffer Substances 0.000 claims description 27
- 239000006167 equilibration buffer Substances 0.000 claims description 25
- 239000000178 monomer Substances 0.000 claims description 25
- 239000012149 elution buffer Substances 0.000 claims description 19
- 238000005406 washing Methods 0.000 claims description 19
- 238000004255 ion exchange chromatography Methods 0.000 claims description 11
- 238000005571 anion exchange chromatography Methods 0.000 claims description 8
- 238000001042 affinity chromatography Methods 0.000 claims description 7
- 239000012634 fragment Substances 0.000 claims description 4
- 102000005962 receptors Human genes 0.000 claims description 3
- 108020003175 receptors Proteins 0.000 claims description 3
- 238000000746 purification Methods 0.000 abstract description 61
- 230000010354 integration Effects 0.000 abstract 1
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 42
- 230000027455 binding Effects 0.000 description 38
- 238000011068 loading method Methods 0.000 description 21
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 20
- 238000010828 elution Methods 0.000 description 18
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 16
- 239000007995 HEPES buffer Substances 0.000 description 16
- 239000004475 Arginine Substances 0.000 description 15
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 15
- 239000012535 impurity Substances 0.000 description 15
- 239000002245 particle Substances 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 13
- 239000000243 solution Substances 0.000 description 13
- 239000012160 loading buffer Substances 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- 238000002835 absorbance Methods 0.000 description 11
- 238000005349 anion exchange Methods 0.000 description 11
- 238000005342 ion exchange Methods 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 229910019142 PO4 Inorganic materials 0.000 description 10
- 239000000356 contaminant Substances 0.000 description 10
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 10
- 239000010452 phosphate Substances 0.000 description 10
- 229910000160 potassium phosphate Inorganic materials 0.000 description 10
- 235000011009 potassium phosphates Nutrition 0.000 description 10
- 238000002965 ELISA Methods 0.000 description 9
- 239000011159 matrix material Substances 0.000 description 9
- 239000011536 extraction buffer Substances 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 230000002829 reductive effect Effects 0.000 description 8
- 239000012557 regeneration buffer Substances 0.000 description 8
- 238000011210 chromatographic step Methods 0.000 description 7
- 238000011084 recovery Methods 0.000 description 7
- 238000001542 size-exclusion chromatography Methods 0.000 description 7
- 102000004472 Myostatin Human genes 0.000 description 6
- 108010056852 Myostatin Proteins 0.000 description 6
- 239000003480 eluent Substances 0.000 description 6
- 238000004128 high performance liquid chromatography Methods 0.000 description 6
- 238000000926 separation method Methods 0.000 description 6
- 238000003998 size exclusion chromatography high performance liquid chromatography Methods 0.000 description 6
- 230000003612 virological effect Effects 0.000 description 6
- 108060003951 Immunoglobulin Proteins 0.000 description 5
- 230000002378 acidificating effect Effects 0.000 description 5
- 239000000427 antigen Substances 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 238000011026 diafiltration Methods 0.000 description 5
- 229940061607 dibasic sodium phosphate Drugs 0.000 description 5
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 238000004191 hydrophobic interaction chromatography Methods 0.000 description 5
- 102000018358 immunoglobulin Human genes 0.000 description 5
- 239000008363 phosphate buffer Substances 0.000 description 5
- 238000011027 product recovery Methods 0.000 description 5
- 238000001742 protein purification Methods 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 238000000108 ultra-filtration Methods 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 4
- 229920002684 Sepharose Polymers 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 239000007983 Tris buffer Substances 0.000 description 4
- 230000002860 competitive effect Effects 0.000 description 4
- 238000011067 equilibration Methods 0.000 description 4
- 239000012537 formulation buffer Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 239000007790 solid phase Substances 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 4
- 238000011179 visual inspection Methods 0.000 description 4
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 3
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 3
- 229920001213 Polysorbate 20 Polymers 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- MZVQCMJNVPIDEA-UHFFFAOYSA-N [CH2]CN(CC)CC Chemical group [CH2]CN(CC)CC MZVQCMJNVPIDEA-UHFFFAOYSA-N 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 229940098773 bovine serum albumin Drugs 0.000 description 3
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 3
- 239000012516 mab select resin Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 3
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 102100038080 B-cell receptor CD22 Human genes 0.000 description 2
- 229910014497 Ca10(PO4)6(OH)2 Inorganic materials 0.000 description 2
- 101100167365 Caenorhabditis elegans cha-1 gene Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 229920005654 Sephadex Polymers 0.000 description 2
- 239000012507 Sephadex™ Substances 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- 125000000129 anionic group Chemical group 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 238000005277 cation exchange chromatography Methods 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 239000003636 conditioned culture medium Substances 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 229940088679 drug related substance Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000005484 gravity Effects 0.000 description 2
- 238000013537 high throughput screening Methods 0.000 description 2
- 229960002885 histidine Drugs 0.000 description 2
- 210000004408 hybridoma Anatomy 0.000 description 2
- 238000001597 immobilized metal affinity chromatography Methods 0.000 description 2
- 229940072221 immunoglobulins Drugs 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000002516 radical scavenger Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- -1 sulfoethyl Chemical group 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical class [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 1
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 1
- 101800000263 Acidic protein Proteins 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 229920006310 Asahi-Kasei Polymers 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 101100283604 Caenorhabditis elegans pigk-1 gene Proteins 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 239000012564 Q sepharose fast flow resin Substances 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 108010029157 Sialic Acid Binding Ig-like Lectin 2 Proteins 0.000 description 1
- 108010057517 Strep-avidin conjugated horseradish peroxidase Proteins 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000001412 amines Chemical group 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 239000003957 anion exchange resin Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000012148 binding buffer Substances 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000005341 cation exchange Methods 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 238000011097 chromatography purification Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000008094 contradictory effect Effects 0.000 description 1
- 239000005289 controlled pore glass Substances 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000002270 exclusion chromatography Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 229960004198 guanidine Drugs 0.000 description 1
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000001471 micro-filtration Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 239000012562 protein A resin Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000004627 regenerated cellulose Substances 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 101150091813 shfl gene Proteins 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000036964 tight binding Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 239000013638 trimer Substances 0.000 description 1
- 238000010977 unit operation Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/165—Extraction; Separation; Purification by chromatography mixed-mode chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
- B01D15/3804—Affinity chromatography
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
- B01D15/3847—Multimodal interactions
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/02—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising inorganic material
- B01J20/04—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising inorganic material comprising compounds of alkali metals, alkaline earth metals or magnesium
- B01J20/048—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising inorganic material comprising compounds of alkali metals, alkaline earth metals or magnesium containing phosphorus, e.g. phosphates, apatites, hydroxyapatites
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/281—Sorbents specially adapted for preparative, analytical or investigative chromatography
- B01J20/282—Porous sorbents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
- C07K16/065—Purification, fragmentation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
- B01D15/361—Ion-exchange
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
- B01D15/3804—Affinity chromatography
- B01D15/3809—Affinity chromatography of the antigen-antibody type, e.g. protein A, G or L chromatography
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Solid-Sorbent Or Filter-Aiding Compositions (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US51401803P | 2003-10-27 | 2003-10-27 | |
| US60/514,018 | 2003-10-27 | ||
| US52333503P | 2003-11-20 | 2003-11-20 | |
| US60/523,335 | 2003-11-20 | ||
| PCT/US2004/032883 WO2005044856A2 (en) | 2003-10-27 | 2004-10-06 | Removal of high molecular weight aggregates using hydroxyapatite chromatography |
| BRPI0415887-3A BRPI0415887B1 (pt) | 2003-10-27 | 2004-10-06 | métodos para a remoção de agregados de elevado peso molecular utilizando cromatografia de hidroxiapatita |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR122020007658B1 true BR122020007658B1 (pt) | 2021-07-27 |
Family
ID=34576743
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0415887-3A BRPI0415887B1 (pt) | 2003-10-27 | 2004-10-06 | métodos para a remoção de agregados de elevado peso molecular utilizando cromatografia de hidroxiapatita |
| BR122020007658-5A BR122020007658B1 (pt) | 2003-10-27 | 2004-10-06 | Método para a remoção de agregados de elevado peso molecular utilizando cromatografia de hidroxiapatita |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0415887-3A BRPI0415887B1 (pt) | 2003-10-27 | 2004-10-06 | métodos para a remoção de agregados de elevado peso molecular utilizando cromatografia de hidroxiapatita |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US9469672B2 (enExample) |
| EP (2) | EP1678208B1 (enExample) |
| JP (2) | JP5004586B2 (enExample) |
| KR (2) | KR101221862B1 (enExample) |
| CN (2) | CN1898266B (enExample) |
| AU (1) | AU2004286938B2 (enExample) |
| BR (2) | BRPI0415887B1 (enExample) |
| CA (1) | CA2543193C (enExample) |
| CO (1) | CO5690649A2 (enExample) |
| DK (2) | DK1678208T3 (enExample) |
| EC (1) | ECSP066583A (enExample) |
| ES (2) | ES2530446T3 (enExample) |
| IL (1) | IL175229A (enExample) |
| MX (1) | MXPA06004472A (enExample) |
| NZ (1) | NZ547315A (enExample) |
| PL (2) | PL2336172T3 (enExample) |
| PT (2) | PT1678208E (enExample) |
| RU (2) | RU2409591C2 (enExample) |
| WO (1) | WO2005044856A2 (enExample) |
Families Citing this family (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0304576D0 (en) * | 2003-02-28 | 2003-04-02 | Lonza Biologics Plc | Protein a chromatography |
| KR101221862B1 (ko) * | 2003-10-27 | 2013-01-14 | 와이어쓰 엘엘씨 | 하이드록시아파타이트 크로마토그래피를 사용한 고분자량응집체의 제거 |
| ES2797480T3 (es) * | 2005-03-11 | 2020-12-02 | Wyeth Llc | Un procedimiento de cromatografía de reparto débil |
| CN101213211A (zh) * | 2005-06-17 | 2008-07-02 | 惠氏公司 | 纯化含Fc区蛋白的方法 |
| KR20080025174A (ko) * | 2005-06-23 | 2008-03-19 | 메디뮨 인코포레이티드 | 응집 및 단편화 프로파일이 최적화된 항체 제제 |
| AR058140A1 (es) * | 2005-10-24 | 2008-01-23 | Wyeth Corp | Metodo de produccion proteica utilizando compuestos anti-senescencia |
| CN101378782A (zh) * | 2005-12-21 | 2009-03-04 | 惠氏公司 | 粘度降低的蛋白质制剂及其用途 |
| US8088833B2 (en) | 2006-04-25 | 2012-01-03 | Tosoh Corporation | Method for purifying an IgG monomer |
| EP2069387A4 (en) * | 2006-06-14 | 2011-02-02 | Glaxosmithkline Llc | METHODS OF PURIFYING ANTIBODIES USING HYDROXYAPATITE CERAMIC |
| CA2661748C (en) * | 2006-08-28 | 2016-02-09 | Alex Eon-Duval | Process for the purification of fc-containing proteins |
| US20100267932A1 (en) * | 2006-08-28 | 2010-10-21 | Alex Eon-Duval | Process for the purification of fc-fusion proteins |
| WO2008031020A2 (en) * | 2006-09-08 | 2008-03-13 | Wyeth | Arginine wash in protein purification using affinity chromatography |
| US8911964B2 (en) | 2006-09-13 | 2014-12-16 | Abbvie Inc. | Fed-batch method of making human anti-TNF-alpha antibody |
| CA2842964A1 (en) | 2006-09-13 | 2008-03-20 | Abbvie Inc. | Cell culture improvements |
| US7691980B2 (en) * | 2007-01-09 | 2010-04-06 | Bio-Rad Laboratories, Inc. | Enhanced capacity and purification of antibodies by mixed mode chromatography in the presence of aqueous-soluble nonionic organic polymers |
| US7999085B2 (en) * | 2007-01-09 | 2011-08-16 | Bio-Rad Laboratories, Inc. | Enhanced capacity and purification of protein by mixed mode chromatography in the presence of aqueous-soluble nonionic organic polymers |
| JP2010516744A (ja) * | 2007-01-26 | 2010-05-20 | メルク セローノ ソシエテ アノニム | 油体技術を用いたＦｃ−融合タンパク質の精製 |
| TW200902708A (en) | 2007-04-23 | 2009-01-16 | Wyeth Corp | Methods of protein production using anti-senescence compounds |
| EP2719705B1 (en) * | 2007-10-26 | 2020-07-29 | Asahi Kasei Kabushiki Kaisha | Method for purifying protein |
| JP5999899B2 (ja) * | 2008-04-08 | 2016-09-28 | バイオ−ラッド ラボラトリーズ インコーポレーティッド | 抗体のクロマトグラフィー精製法 |
| DK2848625T3 (da) † | 2008-08-14 | 2019-10-07 | Genentech Inc | Fremgangsmåder til fjernelse af en kontaminant under anvendelse af ion bytningsmembrankromatografi med forskydning af naturligt forekommende proteiner |
| NZ592095A (en) | 2008-10-20 | 2013-01-25 | Abbott Lab | Isolation and purification of il-12 and tnf-alpha antibodies using protein a affinity chromatography |
| AU2009307737B2 (en) | 2008-10-20 | 2015-07-23 | Abbvie Inc. | Viral inactivation during purification of antibodies |
| CA2738243C (en) | 2008-10-29 | 2020-09-29 | Wyeth Llc | Formulations of single domain antigen binding molecules |
| CN102272154A (zh) * | 2008-10-29 | 2011-12-07 | 惠氏有限责任公司 | 单域抗原结合性分子的纯化方法 |
| ES2699434T3 (es) * | 2008-10-31 | 2019-02-11 | Wyeth Llc | Purificación de proteínas ácidas utilizando cromatografía de hidroxiapatita cerámica |
| AU2010260476A1 (en) * | 2009-03-11 | 2011-10-13 | Wyeth Llc | Methods of purifying small modular immunopharmaceutical proteins |
| US8481694B2 (en) | 2009-04-29 | 2013-07-09 | Bio-Rad Laboratories, Inc. | Purification of immunoconjugates |
| WO2011001963A1 (ja) | 2009-07-03 | 2011-01-06 | 旭化成ケミカルズ株式会社 | 多孔質基材に固定されたグラフト鎖に結合しているアミノ基及びアルキル基を有する多孔膜を用いた抗体の精製方法 |
| RU2603055C2 (ru) | 2009-10-20 | 2016-11-20 | Эббви Инк | Выделение и очистка антител против il-13 с применением аффинной хроматографии с белком а |
| CA2784278C (en) | 2009-12-18 | 2019-02-26 | Novartis Ag | Wash solution and method for affinity chromatography |
| US20130116413A1 (en) * | 2009-12-29 | 2013-05-09 | Dr. Reddy's Laboratories, Inc. | Purification of proteins |
| JP5773454B2 (ja) * | 2010-01-15 | 2015-09-02 | バイオ−ラッド ラボラトリーズ インコーポレーティッド | アパタイトの表面中和方法 |
| JP5737817B2 (ja) * | 2010-04-14 | 2015-06-17 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 免疫グロブリン凝集体の除去 |
| GB201006753D0 (en) | 2010-04-22 | 2010-06-09 | Biotest Ag | Process for preparing an immunolobulin composition |
| WO2011156073A1 (en) * | 2010-06-08 | 2011-12-15 | Millipore Corporation | Removal of protein aggregates from biopharmaceutical preparations using calcium phosphate salts |
| US8895707B2 (en) * | 2010-08-18 | 2014-11-25 | Bio-Rad Laboratories, Inc. | Elution of proteins from hydroxyapatite resins without resin deterioration |
| KR20130131352A (ko) * | 2010-11-01 | 2013-12-03 | 디에스엠 아이피 어셋츠 비.브이. | 단일 유닛 이온 교환 크로마토그래피 항체 정제 |
| EP2670704B1 (en) | 2011-02-02 | 2018-12-12 | Bio-Rad Laboratories, Inc. | Apatite surface neutralization with alkali solutions |
| CN103717284B (zh) * | 2011-06-08 | 2016-02-24 | 新加坡科技研究局 | 通过约束共水合色谱纯化生物制品 |
| MX2013014615A (es) * | 2011-06-16 | 2014-02-17 | Dsm Ip Assets Bv | Purificacion de anticuerpos por cromatografia de unidad unica. |
| SG10201701224UA (en) | 2012-03-12 | 2017-04-27 | Merck Patent Gmbh | Removal of protein aggregates from biopharmaceutical preparations in a flowthrough mode |
| WO2013180933A1 (en) | 2012-05-30 | 2013-12-05 | Bio-Rad Laboratories, Inc. | In situ restoration of apatite-based chromatography resins |
| WO2014003142A1 (ja) * | 2012-06-27 | 2014-01-03 | 旭化成メディカル株式会社 | 抗体 |
| JP2014105180A (ja) * | 2012-11-27 | 2014-06-09 | Hoya Corp | モノマー化方法 |
| CN107693781B (zh) | 2013-03-13 | 2021-11-09 | 巴扎德制药公司 | 用于眼部递送的嵌合细胞因子制剂 |
| HK1222871A1 (zh) * | 2013-05-13 | 2017-07-14 | Medimmune, Llc | 具有最小单体分离的重组多克隆抗体多聚体的分离 |
| KR20160029840A (ko) | 2013-07-05 | 2016-03-15 | 라보라토이레 프란카이즈 듀 프락티온네먼트 에트 데스 바이오테크놀로지스 | 친화성 크로마토그래피 매트릭스 |
| EP3019262A1 (en) | 2013-07-12 | 2016-05-18 | Merck Patent GmbH | Removal of fragments from a sample containing a target protein using activated carbon |
| JP6479305B2 (ja) | 2013-07-12 | 2019-03-06 | 株式会社Ｕｍｎファーマ | ウイルス様粒子の精製方法 |
| JP6326499B2 (ja) | 2013-12-12 | 2018-05-16 | イー・エム・デイー・ミリポア・コーポレイシヨン | アクリルアミド含有フィルターを使用したタンパク質分離 |
| IL296754A (en) * | 2013-12-27 | 2022-11-01 | Chugai Pharmaceutical Co Ltd | A method for isolating an antibody with a low isoelectric point |
| EP3157863B1 (en) | 2014-06-23 | 2023-06-21 | Bio-Rad Laboratories, Inc. | Apatite in-situ restoration |
| WO2015200282A1 (en) | 2014-06-23 | 2015-12-30 | Bio-Rad Laboratories, Inc. | Apatite pretreatment |
| EP3233230B1 (en) | 2014-12-15 | 2024-06-12 | Merck Patent GmbH | Target molecule capture from crude solutions |
| MX395730B (es) | 2015-03-13 | 2025-03-25 | Bristol Myers Squibb Co | Uso de lavados alcalinos durante la cromatografia para remover impurezas. |
| US11661438B2 (en) | 2015-12-21 | 2023-05-30 | Pfizer, Inc. | Purification of antibody drug conjugates using a sodium phosphate gradient |
| US11919924B1 (en) * | 2016-03-15 | 2024-03-05 | Fresenius Kabi Deutschland Gmbh | Methods of purifying and producing an adalimumab antibody |
| US11186858B1 (en) | 2016-03-15 | 2021-11-30 | Fresenius Kabi Deutschland Gmbh | Methods for increasing biosimilarity |
| CN106977591B (zh) * | 2017-05-04 | 2020-05-05 | 广州康盛生物科技股份有限公司 | 一种分离纯化重组葡萄球菌蛋白a的方法 |
| EP3672981A4 (en) | 2017-08-22 | 2021-09-15 | Biogen MA Inc. | PROCESSES FOR PURIFYING ANTIBODIES PRESENTING REDUCED AGGREGATES WITH HIGH MOLECULAR WEIGHT |
| WO2019116096A1 (en) * | 2017-12-15 | 2019-06-20 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Production of fc fragments |
| CA3034795A1 (en) * | 2018-02-27 | 2019-08-27 | Pfizer Inc. | Antibody purification |
| WO2019183334A1 (en) | 2018-03-21 | 2019-09-26 | Waters Technologies Corporation | Non-antibody high-affinity-based sample preparation, sorbents, devices and methods |
| US20210024573A1 (en) | 2018-04-03 | 2021-01-28 | Merck Patent Gmbh | Cex chromatography media and low salt elution of target proteins from biopharmaceutical feeds |
| JP6951051B2 (ja) * | 2018-05-24 | 2021-10-20 | ＨＯＹＡ Ｔｅｃｈｎｏｓｕｒｇｉｃａｌ株式会社 | 吸着剤の生産方法 |
| JP6704074B2 (ja) * | 2019-02-04 | 2020-06-03 | 株式会社Ｕｍｎファーマ | ウイルス様粒子の精製方法 |
| WO2021099536A1 (en) | 2019-11-22 | 2021-05-27 | Morphosys Ag | Method to increase antibody yield during ion exchange chromatography |
| JP2020099909A (ja) * | 2020-03-17 | 2020-07-02 | ＨＯＹＡ Ｔｅｃｈｎｏｓｕｒｇｉｃａｌ株式会社 | 処理方法、生産方法およびハイドロキシアパタイト充填剤 |
| MX2022012278A (es) | 2020-03-30 | 2022-10-27 | Ablynx Nv | Metodo para la produccion y purificacion de dominios variables unicos de inmunoglobulina multivalentes. |
| WO2021220251A1 (en) * | 2020-05-01 | 2021-11-04 | Kashiv Biosciences, Llc | An improved process of purification of protein |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US523335A (en) | 1894-07-24 | Air-bolt for flour-mills | ||
| US419964A (en) | 1890-01-21 | Transom-lifter | ||
| US428894A (en) | 1890-05-27 | Process of making tool-handles | ||
| US514018A (en) | 1894-02-06 | Edward j | ||
| US4745183A (en) * | 1984-02-21 | 1988-05-17 | Bio-Rad Laboratories, Inc. | Use of hydroxylapatite for the analysis and preparation of purified monoclonal antibodies |
| JPH03291300A (ja) * | 1989-12-28 | 1991-12-20 | Mitsui Toatsu Chem Inc | ポリクローナル抗体の分離方法 |
| GB9022545D0 (en) * | 1990-10-17 | 1990-11-28 | Wellcome Found | Culture medium |
| PE20020574A1 (es) * | 2000-12-06 | 2002-07-02 | Wyeth Corp | Anticuerpos humanizados que reconocen el peptido amiloideo beta |
| MXPA04006053A (es) | 2001-12-21 | 2005-03-31 | Immunex Corp | Metodos para purificacion de proteina. |
| CA2516518A1 (en) | 2003-02-28 | 2004-09-10 | Lonza Biologics Plc. | Antibody purification by protein a and ion exchange chromatography |
| KR101221862B1 (ko) * | 2003-10-27 | 2013-01-14 | 와이어쓰 엘엘씨 | 하이드록시아파타이트 크로마토그래피를 사용한 고분자량응집체의 제거 |
-
2004
- 2004-10-06 KR KR1020067010375A patent/KR101221862B1/ko not_active Expired - Lifetime
- 2004-10-06 DK DK04794288.3T patent/DK1678208T3/da active
- 2004-10-06 CA CA2543193A patent/CA2543193C/en not_active Expired - Fee Related
- 2004-10-06 WO PCT/US2004/032883 patent/WO2005044856A2/en not_active Ceased
- 2004-10-06 CN CN2004800387536A patent/CN1898266B/zh not_active Expired - Lifetime
- 2004-10-06 PT PT47942883T patent/PT1678208E/pt unknown
- 2004-10-06 JP JP2006538022A patent/JP5004586B2/ja not_active Expired - Lifetime
- 2004-10-06 BR BRPI0415887-3A patent/BRPI0415887B1/pt not_active IP Right Cessation
- 2004-10-06 ES ES10174366T patent/ES2530446T3/es not_active Expired - Lifetime
- 2004-10-06 PL PL10174366T patent/PL2336172T3/pl unknown
- 2004-10-06 NZ NZ547315A patent/NZ547315A/en unknown
- 2004-10-06 US US10/958,595 patent/US9469672B2/en active Active
- 2004-10-06 CN CN201110221442.5A patent/CN102276717B/zh not_active Expired - Lifetime
- 2004-10-06 DK DK10174366.4T patent/DK2336172T3/en active
- 2004-10-06 AU AU2004286938A patent/AU2004286938B2/en not_active Expired
- 2004-10-06 RU RU2006113695/10A patent/RU2409591C2/ru active
- 2004-10-06 PL PL04794288T patent/PL1678208T3/pl unknown
- 2004-10-06 BR BR122020007658-5A patent/BR122020007658B1/pt active IP Right Grant
- 2004-10-06 MX MXPA06004472A patent/MXPA06004472A/es active IP Right Grant
- 2004-10-06 ES ES04794288T patent/ES2418830T3/es not_active Expired - Lifetime
- 2004-10-06 EP EP04794288.3A patent/EP1678208B1/en not_active Expired - Lifetime
- 2004-10-06 EP EP10174366.4A patent/EP2336172B1/en not_active Expired - Lifetime
- 2004-10-06 PT PT101743664T patent/PT2336172E/pt unknown
- 2004-10-06 KR KR1020117030940A patent/KR101321876B1/ko not_active Expired - Lifetime
-
2006
- 2006-04-26 IL IL175229A patent/IL175229A/en active IP Right Grant
- 2006-05-19 CO CO06048228A patent/CO5690649A2/es not_active Application Discontinuation
- 2006-05-25 EC EC2006006583A patent/ECSP066583A/es unknown
-
2010
- 2010-09-24 RU RU2010139827/10A patent/RU2573910C2/ru active
-
2012
- 2012-01-26 JP JP2012013648A patent/JP5490156B2/ja not_active Expired - Lifetime
-
2013
- 2013-03-14 US US13/803,071 patent/US9822143B2/en not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR122020007658B1 (pt) | Método para a remoção de agregados de elevado peso molecular utilizando cromatografia de hidroxiapatita | |
| US7385040B2 (en) | Antibody purification | |
| US7714112B2 (en) | Method of antibody purification | |
| JP4198751B2 (ja) | 抗体の精製 | |
| US10730908B2 (en) | Separation method | |
| CN101043947B (zh) | 一种纯化抗体的方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 06/10/2004, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO. |